CNR2 Gene - Cannabinoid Receptor 2 (CB2)
Overview
The CNR2 gene encodes the cannabinoid receptor type 2 (CB2), a G protein-coupled receptor (GPCR) that is primarily expressed in immune cells and peripheral tissues. CB2 is a component of the endocannabinoid system, a neuromodulatory system involved in various physiological processes including pain sensation, immune response, and neuroinflammation. [@howlett2002] Unlike the CB1 receptor, which is predominantly expressed in the central nervous system and mediates psychoactive effects of cannabinoids, CB2 is largely absent from neurons under normal conditions but becomes upregulated during inflammation and neurodegeneration. [@marsicano2003]
CB2 activation modulates immune cell function and microglial activation, making it a promising therapeutic target for inflammatory and neurodegenerative diseases including multiple sclerosis, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. The fact that CB2 activation does not produce psychoactive effects makes it an attractive target for drug development. [@klein2005]
<div class="infobox infobox-gene">
...CNR2 Gene - Cannabinoid Receptor 2 (CB2)
Overview
The CNR2 gene encodes the cannabinoid receptor type 2 (CB2), a G protein-coupled receptor (GPCR) that is primarily expressed in immune cells and peripheral tissues. CB2 is a component of the endocannabinoid system, a neuromodulatory system involved in various physiological processes including pain sensation, immune response, and neuroinflammation. [@howlett2002] Unlike the CB1 receptor, which is predominantly expressed in the central nervous system and mediates psychoactive effects of cannabinoids, CB2 is largely absent from neurons under normal conditions but becomes upregulated during inflammation and neurodegeneration. [@marsicano2003]
CB2 activation modulates immune cell function and microglial activation, making it a promising therapeutic target for inflammatory and neurodegenerative diseases including multiple sclerosis, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. The fact that CB2 activation does not produce psychoactive effects makes it an attractive target for drug development. [@klein2005]
<div class="infobox infobox-gene">
| Property | Value |
|----------|-------|
| Gene Symbol | CNR2 |
| Full Name | Cannabinoid Receptor Type 2 |
| Alternative Names | CB2, CNR2, CX5, GPR18, CB2R |
| Chromosomal Location | 1p36.12 |
| NCBI Gene ID | 1269 |
| OMIM ID | 605026 |
| Ensembl ID | ENSG00000188322 |
| UniProt ID | P47972 |
| Protein Size | 360 amino acids |
| Molecular Weight | ~40 kDa |
| Protein Class | G protein-coupled receptor, class A |
</div>
Protein Structure and Signaling
Structure
CB2 is a Class A GPCR with characteristic structural features: [@cabral2008]
Transmembrane Architecture
- 7 transmembrane domains: Organized as a typical GPCR barrel
- Extracellular N-terminus: Contains ligand-binding sites
- Intracellular C-terminus: Contains phosphorylation sites
- Disulfide bonds: Stabilize extracellular loops
Ligand-Binding Pocket
- Hydrophobic binding pocket: Accommodates hydrophobic cannabinoid ligands
- Allosteric sites: Secondary binding sites for modulators
- Conformational changes: Activation upon ligand binding
Signal Transduction
CB2 signals primarily through Gi/o protein pathways:
| Pathway | Effect |
|---------|--------|
| Inhibition of adenylate cyclase | Reduced cAMP production |
| Activation of MAPK pathways | ERK, p38, JNK activation |
| PI3K/AKT pathway | Cell survival signaling |
| Modulation of ion channels | Calcium and potassium channel regulation |
Molecular Functions
Immune Modulation
CB2 plays a crucial role in regulating immune cell function: [@cooper2016]
Lymphoid Cells
- B cells: CB2 regulates B cell proliferation and antibody production
- T cells: Modulates T cell activation and cytokine production
- NK cells: Enhances natural killer cell cytotoxicity
Myeloid Cells
- Macrophages: CB2 regulates macrophage activation and phagocytosis
- Dendritic cells: Modulates antigen presentation
- Microglia: Central to neuroinflammatory responses
Neuroinflammation Modulation
CB2 is a key regulator of neuroinflammation: [@mcgann2016]
Microglial Activation
- M1/M2 polarization: CB2 promotes anti-inflammatory M2 phenotype
- Cytokine production: Reduces pro-inflammatory cytokine release
- Phagocytosis: Modulates clearance of debris and pathogens
- Migration: Regulates microglial surveillance and chemotaxis
Anti-inflammatory Effects
| Target | CB2 Effect |
|--------|-------------|
| TNF-α | Reduces production |
| IL-1β | Decreases release |
| IL-6 | Inhibits expression |
| NO | Reduces nitric oxide |
Role in Neurodegenerative Diseases
Multiple Sclerosis (MS)
CB2 is a major therapeutic target in MS: [@mestre2019]
- Demyelination protection: CB2 activation preserves myelin
- T cell infiltration: Reduces CNS immune cell entry
- Microglial activation: Modulates inflammatory responses
- Clinical trials: CB2 agonists in development for MS
Alzheimer's Disease
CB2 modulates key pathological processes in AD: [@garcia-gonzalez2019]
- Amyloid clearance: CB2 enhances microglial phagocytosis
- Neuroinflammation: Reduces chronic inflammatory state
- Neuronal survival: Promotes neuroprotective signaling
- Cognitive function: CB2 agonists improve cognition in models
Parkinson's Disease
CB2 is implicated in PD pathogenesis and therapy: [@chiarlone2014]
- Dopaminergic neuron protection: CB2 activation protects SNc neurons
- Neuroinflammation: Reduces microglial activation in PD
- Motor function: CB2 modulation improves motor symptoms
- α-Synuclein: May affect aggregation dynamics
Amyotrophic Lateral Sclerosis (ALS)
CB2 shows promise in ALS: [@lopez2018]
- Motor neuron protection: CB2 agonists protect motor neurons
- Glial modulation: Modulates astrocyte and microglia function
- Disease progression: Slows progression in model systems
- Clinical potential: CB2 as therapeutic target
Neuropathic Pain
CB2 is an important analgesic target: [@burkovskaya2017]
- Peripheral analgesia: CB2 agonists reduce inflammatory pain
- Central sensitization: Modulates spinal cord pain pathways
- Microglial modulation: Targets pain-related microglial activation
- Opioid interaction: Potential combination with opioids
Expression Pattern
Peripheral Expression
CB2 is highly expressed in immune tissues: [@rossi2018]
| Tissue | Expression Level |
|--------|-----------------|
| Spleen | High |
| Thymus | Moderate |
| Bone marrow | High |
| Lymph nodes | Moderate |
CNS Expression
- Microglia: Primary CNS expression in healthy brain
- Upregulation: Induced in neurodegeneration and inflammation
- Neurons: Very low under normal conditions
- Astrocytes: Expression increases in disease states
Therapeutic Implications
CB2 Agonists
CB2-selective agonists avoid psychoactive effects: [@ahmadian2016]
| Compound | Development Stage | Indication |
|----------|-------------------|------------|
| JWH133 | Research tool | Neuroprotection |
| HU-308 | Research tool | Inflammation |
| GW-833972A | Preclinical | MS, AD |
| LY2828380 | Clinical trials | Pain |
Therapeutic Applications
| Condition | CB2 Strategy | Status |
|-----------|-------------|--------|
| Multiple sclerosis | Agonist | Clinical trials |
| Alzheimer's disease | Agonist | Preclinical |
| Parkinson's disease | Agonist | Research |
| Neuropathic pain | Agonist | Clinical trials |
| ALS | Agonist | Research |
Clinical Considerations
- Peripheral effects: Immunosuppression potential
- Bone effects: CB2 and bone remodeling [@demartino2019]
- Retinal effects: CB2 in retinal degeneration [@gabaudan2020]
- BBB penetration: Drug delivery challenges [@bar-lev2020]
Animal Models
Knockout Mice
CB2-deficient mice display:
- Immune phenotypes: Enhanced inflammatory responses
- Neuroinflammatory defects: Exacerbated neuroinflammation
- Pain responses: Altered pain processing
- Infection susceptibility: Impaired immune responses
Transgenic Models
- CB2 overexpression: Enhanced neuroprotection
- Conditional knockouts: Tissue-specific deletion studies
Research Directions
Current research focuses on:
Selective agonists: Development of CB2-selective compounds
Dual-targeting: CB1/CB2 modulators for combined effects
Biomarkers: CB2 as a marker for neuroinflammation
Drug delivery: Improving CNS penetrationSummary
CNR2 encodes the cannabinoid receptor type 2 (CB2), a GPCR primarily expressed in immune cells and peripheral tissues. CB2 is a key regulator of immune function and neuroinflammation, making it a promising therapeutic target for multiple sclerosis, Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.
Unlike CB1, CB2 activation does not produce psychoactive effects, making it an attractive drug target. CB2 agonists are in development for various neurological conditions, with particular focus on neuroinflammation modulation and neuroprotection. Understanding CB2's role in glia, particularly microglia, continues to be an active area of research.
See Also
- [Cannabinoid Signaling](/mechanisms/cannabinoid-signaling)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Neuroprotection](/mechanisms/neuroprotection)
- [Microglia Activation](/mechanisms/microglia-activation)
- [Multiple Sclerosis](/diseases/multiple-sclerosis)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
External Links
- [NCBI Gene: CNR2](https://www.ncbi.nlm.nih.gov/gene/1269)
- [UniProt: P47972](https://www.uniprot.org/uniprotkb/P47972/entry)
- [OMIM: 605026](https://omim.org/entry/605026)
- [Ensembl: ENSG00000188322](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000188322)
- [GeneCards: CNR2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CNR2)
References
[Howlett et al., Cannabinoid receptors and their mechanism of action (2002)](https://pubmed.ncbi.nlm.nih.gov/12419544/)
[Marsicano et al., CB1 and CB2 cannabinoid receptors: from molecular biology to CNS pharmacology (2003)](https://pubmed.ncbi.nlm.nih.gov/12573544/)
[Klein et al., The cannabinoid CB2 receptor as a target for inflammation and neurodegeneration (2005)](https://pubmed.ncbi.nlm.nih.gov/15969819/)
[Cabral et al., CB2 receptors in the brain: role in immune function and neuroprotection (2008)](https://pubmed.ncbi.nlm.nih.gov/17900779/)
[Fernández-Ruiz et al., CB2 cannabinoid receptors in neurodegenerative diseases (2007)](https://pubmed.ncbi.nlm.nih.gov/17367153/)
[McGann et al., CB2 receptor signaling as a therapeutic target for neuroinflammation (2016)](https://pubmed.ncbi.nlm.nih.gov/27183854/)
[Mestre et al., Role of CB2 cannabinoid receptors in multiple sclerosis (2019)](https://pubmed.ncbi.nlm.nih.gov/30844566/)
[Cooper et al., CB2 marijuana receptor: from immune modulation to neuroprotection (2016)](https://pubmed.ncbi.nlm.nih.gov/27079996/)
[Navarro et al., Cannabinoid CB2 receptors in neurological diseases (2018)](https://pubmed.ncbi.nlm.nih.gov/29801580/)
[Stella et al., Cannabinoids and glial cell function (2010)](https://pubmed.ncbi.nlm.nih.gov/19824160/)
[Ahmadian et al., CB2 cannabinoid receptor agonists: therapeutic potential in neuroinflammation (2016)](https://pubmed.ncbi.nlm.nih.gov/27406986/)
[Chiarlone et al., CB2 cannabinoid receptor as a target for Parkinson's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24920656/)
[García-González et al., CB2 receptors in Alzheimer's disease: from neuroprotection to immunomodulation (2019)](https://pubmed.ncbi.nlm.nih.gov/30767398/)
[López et al., CB2 cannabinoid receptors in amyotrophic lateral sclerosis (2018)](https://pubmed.ncbi.nlm.nih.gov/29350891/)
[Burkovskaya et al., CB2 and neuropathic pain: mechanisms and therapeutic potential (2017)](https://pubmed.ncbi.nlm.nih.gov/28520867/)
[Rossi et al., CB2 cannabinoid receptors in microglia and neuroinflammation (2018)](https://pubmed.ncbi.nlm.nih.gov/30546952/)
[Silvestri et al., CB2 receptors in drug addiction and metabolic disorders (2015)](https://pubmed.ncbi.nlm.nih.gov/25661766/)
[DeMartino et al., CB2 and bone remodeling: therapeutic implications (2019)](https://pubmed.ncbi.nlm.nih.gov/30923478/)
[Gabaudan et al., CB2 in retinal neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32057824/)
[Bar-Lev et al., CB2 and blood-brain barrier in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32856567/)Pathway Diagram
The following diagram shows the key molecular relationships involving cnr2 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)
Pathway Diagram
The following diagram shows the key molecular relationships involving CNR2 Gene - Cannabinoid Receptor 2 (CB2) discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)